

Subject Index

BR: Book review
CR: Conference report

A

- A68930 (D₁-like agent) 336
- A86929 (D₁-like agent) 336
- AAV-CFTR gene therapy, trials 5
- Abl-kinase inhibitors 162
- α -Acetoxysulfides 516
- Acetylcholine receptors
 - muscarinic, *see* Muscarinic receptors
 - nicotinic receptor ligand 247
- N-Acetylneuraminic acid, synthesis 518
- Acids, dissociation/ionization 461
- Acid sphingomyelinase, changes in senescent cells 70
- Actinomycetes, polyketide synthesis 258–259, 522
- Activity, structure relationship, *see* Structure–activity relationships
- Activity–activity relationships, QSAR application 541–542
- Acyclovir 235
 - biocatalysis 521
- Acylation, regioselective 518
- Acyl-CoA:cholesterol acyltransferase (ACAT), inhibitors 123
 - trisubstituted ureas 352
- Additive fuzzy density fragmentation approach (AFDF) 133–134
- Adefovir 235, 242
- Adeno-associated virus (AAV) CFTR gene therapy for cystic fibrosis 5
 - as vector for α -glucosidase gene therapy 5
- Adenophostins 214
- Adenosine agonists 280–281
- A₁-Adenosine antagonist 499–500
- A₃-Adenosine receptor, ligands 35
- S-Adenosylhomocysteine hydrolase, antiviral nucleosides 236
- Adhesion molecules
 - soluble 198–199
 - see also* Cell adhesion molecules (CAMs)
- Adjuvants, vaccine 403, 404
- α_{2A} -Adrenergic receptors, dexmedetomidine action 38
- β_3 -Adrenoceptor agonists, obesity and 363
- β -Adrenoceptors
 - blockers, *see* β -blockers
 - changes in senescent cells and ageing 69
- Adrenocortical cells, changes in ageing 69
- Adrenoleucodystrophy 510
- Advanced glycation end products 129
- Advanced Technologies for Information Extraction: Analysis of Complex Data Sets to Aid Drug Discovery* (CR) 43–45
- Adverse drug reactions, elderly 65
- AFDF principle 133–134
- Ageing 64–71
 - cellular hypothesis 66–67
 - programmed/unprogrammed 66–67
- Age-related diseases 64–66
- Aggregation constants 425
- AGM1470 (TNP 470) 60
- Agouti mouse 129
- AIDS
 - antiviral L-nucleosides 237
 - HIV protease inhibitor use, *see* HIV protease inhibitors
 - phosphodiesterase inhibitors 278
 - see also* HIV-1
- AIDS Clinical Trials Group 160
- β -Alanine, electron density images 136
- Alcohol dehydrogenase 520
- Alcon Laboratories, Chiroscience alliance 354
- Alkoxy-oxadiazolyl-tetrahydropyridines 345
- Allergan, tazarotene 498
- Allergen-induced bronchoconstriction, phosphodiesterase 4 (PDE4) inhibitors effect 98
- Alniditan 297, 298
- Alzheimer's disease
 - free radicals role 225
 - genotyping 311
 - Mitokor's research 211
- American Chemical Society (ACS) National Meeting (213th)* (CR) 362–364
- Amidines, linker for 447
- Aminimides 256
- Amino acid piperidines 291
- Amino acids, neurotoxic 353
- 3-Amino-1,2-benzisoxazoles 248
- 7-Aminocephalosporanic acid, synthesis 528
- 2-Aminoethyl amide 279
- α -Amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA), *see* AMPA
- 6-Aminopenicillanic acid, synthesis 528
- 2-Aminothiazoles 216
- Amoxycillin, synthesis 528
- AMPA 35, 222
 - receptors 222, 223
- AMPA receptor antagonists 35, 122, 220, 223
 - novel 301
- Amylin 254
- Amyotrophic lateral sclerosis (ALS) 522
 - free radicals role 225
- Anaesthesia, ideal, developments towards 38
- Anaesthetics, local, RAC421 143
- Analgesia, effectiveness in ethnic groups 456
- Analytical techniques, solid-phase organic and combinatorial synthesis 102–189
- Androstenedione, biotransformation 529–530
- Angiogenesis 50–51
 - inhibition, receptor tyrosine kinases as targets 50–63
 - inhibitors in development, classes 60–61
 - receptor tyrosine kinases (RTKs) role 52–58
 - in solid tumours 51, 58–59, 61
 - see also* Anti-angiogenic drugs
- Angiogenic factors 53
- Angiostatin, angiogenic inhibitor 60
- Angiotensin-converting enzyme expression change in senescence 69
 - inhibitors, biocatalysis 514
- Angiotensin II, antagonists 352
- Anhydrohexitol nucleoside 239
- 4-Anilino-6-aminopyrimidines 80
- Anti-adhesion molecules, arthritis therapy 433
- Anti-angiogenic drugs
 - applications 61–62
 - in development and classes 60–61
 - receptor tyrosine kinases as targets 50–63
 - see also* Angiogenesis
- Anti-angiogenic factors 53
- Antiarthritic drugs 427–435
 - see also* Rheumatoid arthritis
- Antibacterial activity, solution libraries 556
- Antibiotics
 - angiogenesis inhibitors 60
 - effective against MRSA 446
 - from natural products, new 257–258
 - genome sequencing and drug prospects 510

- Gram-negative bacteria 162
Gram-positive bacteria
 drugs under development 47
 new drugs 257–258
lipophilic carbapenems 35
polyene 35
resistance 446
 Gram-positive bacteria 47–49
 methicillin 35, 47, 446
- Antibodies, *see* Humanized antibodies; Monoclonal antibodies
- Anticancer agents
 artificial ion channel strategy 452
 arylsulphonylimidazolidinones 80
 duocarmycins and CC1065 304
 epothilones 87–88
 experimental and clinical (BR) 217
 fostriecin (C1920) 248
 from OBOC libraries 124
 photodynamic therapy-associated 449
 preclinical studies of COLLAMERS™ 160
 second generation taxoids 161
- Anticonvulsants, new class 393
- Anti-FLK-1 monoclonal antibody (DC101) 60
- Antifolates, non-glutamate type 34
- Antifungal agents
 antibacterial solution library and 556
 azole 34–35
 SCH56592, synthesis 522
 FEMSTAT and FDA approval 130
 genome sequencing and drug prospects 510
 new, from natural products 258
- Antigen, tolerance induction 432–433
- Antihistamines, new natural products 555
- Antihypertensive agents
 neuropeptide Y₁ receptor antagonists 23
 novel 393
 serotonergic 297, 298–299
 see also Hypertension
- Anti-inflammatory action, phosphodiesterase 4 inhibitors 98–99
- Anti-inflammatory drugs 325–332
 COX-2 inhibitors 393
 thalidomide 276–278
 see also COX-2 inhibitors; *other drug groups*; Thalidomide
- Antimalarial drugs, novel 34
- Antimuscarinic agents, *see* Muscarinic M₁ antagonist
- Anti-obesity drugs, new targets 164
- Antioxidants 225
 new natural products 555
- Antiparasitic agents
 binaphthalene 391–392
 picidin activity against histone deacetylase 82
- Antiplatelet agents 396
- Antiproliferative compounds, in arthritis 433–434
- Antiprotozoal drugs, apicidin activity against histone deacetylase 82
- Antisense oligonucleotide, vascular endothelial growth factor (VEGF) 61
- Antispasmodics 247
- Antispermatic compounds 500
- Antithrombotic RGD mimetics 34
- Anti-VEGF monoclonal antibody 60
- Antiviral activity, nucleoside analogues 235–242
- Antiviral agents, *see entries beginning* HIV; Hepatitis B virus
- Antiviral nucleosides
 1263W94 238
 1592U89 238, 240–241
 carbocyclic 239, 241
 mode of action and spectrum of activity 241–242
 new developments 238–240
 pharmacokinetics/pharmacodynamics 240–241
 phosphorylation 240, 242
- Antril 429
- Apicidin 82
- Apicomplexan parasites 82
- Apo-2L 448
- Apoptosis 226–227
 blockers 226
 c-fos-mediated 305
 neuronal cells 219, 221, 226–227
 new regulatory pathway 448
- Aprophen 345–346
- Arachidonic acid, release/metabolism, inhibitors 325–328
- Architectural structure, of R&D in collaborations 200–205
- Argonaut Technologies, polystyrene resin for solid-phase organic synthesis 454
- Aromatase inhibitors 351
- Aroyl(aminoacyl)pyrroles 393
- Arpromidine 21
- Array-based technologies 315–324
 cDNA libraries 317, 318
- Arthritis, *see* Rheumatoid arthritis
- Arylamides 493
- 2-Aryloxycarbonylthiophene-3-sulphonamides 500
- Aryl piperazine 362
- 4-Aryl-5-pyridinylimidazoles 35
- Arylsulphonylimidazolidinones, as anticancer agents 80
- Aryltricyclospirodienones 351
- Aspartic protease 83, 262
 HIV encoding 6
 inhibitors 256, 262
- Asthma 96
 5-lipoxygenase inhibitor treatment 248
 phosphodiesterase 4 inhibitors 89, 96–99
- Atenolol, biocatalysis 515, 516
- Atherosclerosis
 angiogenesis inhibitors application 61
 plaques, ICAM-1 expression 198
- Atiprimod 434
- Atmospheric pressure ionization (API) 532–537
- ATP-sensitive potassium channel openers 249, 303
- Auda Pharmaceuticals 175
- Aurintricarboxylic acids, monomeric 494, 495
- Aurora Biosciences, research and licensing agreement 49
- Automated array technologies 315–324
- Automation
 cDNA library analysis 321–323
 drug discovery 40–43
 genome sequencing 511
 HTS, *see* High-throughput screening
 isolation of natural products 257
 pipetting devices 395
 time-resolved fluorometry 378–381
 see also Robotics
- The Automation Partnership, genomics processing modules 454
- Azasugars, synthesis 518
- Azole antifungals 34–35
 SCH56592 522

B

- B61 receptor, epithelial cell kinase (ECK) 53, 57
- Baclofen, enantiomer synthesis 517
- Bacteria
 genetic profiling 310
 genome sequencing 510
 vectors for vaccines 404
- Bactericidal/permeability-increasing (BPI) protein 60
- Bases, dissociation/ionization 461
- Basic fibroblast growth factor (bFGF)
 carbohydrate inhibitor (GM1474) 60
 glyceptor mimetic inhibitor (GL 14.2) 60
- Batimastat 61, 216, 279

- bax* gene 226
 BAY12803 47, 49
 BayK8644, stereoselectivity 144
 BB2117 327
bcl-2 gene 226
 Bcr-Abl protein 162
 Belladonna alkaloids 341
 Benazepril, prodrug and uptake of 152
 Benextramine 20–21
 Benzhydryl derivatives 348
 1,4-Benzodiazepine 163
 Benzodiazepine, second generation 286–288
 Benzodiazepine derivatives, CCK_B/gastrin receptor antagonists 286–288
 1,4-Benzodiazepine-2,5-diones 163
 Benzodiazepinediones, solid-phase synthesis 304
 Benzophenanthrene molecules, electron density image 134, 135
 Benzo-thiopyranopyrazoles 122
 Benzoxazepinone 215, 216
 Berenil 490
 β -blockers
 biocatalysis 516
 as CYP2D6 substrates 483
 enantiomer synthesis 516
 in heart failure 115
 BIBP3226 22–23
 Bicyclic heteroaromatic derivatives, CCK_B/gastrin receptor antagonists 290
 Bicyclic HIV protease inhibitors 79
 Bicyclodioxolane analogues 347–348
 Bicyclo[3.1.0]hexane nucleoside 239
 Big endothelin-1 (big ET-1) 85
 Binaphthalene, novel 391–392
 Bioactive peptides 38
 Bioavailability
 oral, *see* Oral bioavailability
 peptidomimetic drugs 166
 Biocatalysis
 applications 513–531
 enantiomers of NSAIDs 514
 laboratory-scale synthesis 513–522
 large-scale synthesis 522–530
 Biodiversity, natural products from marine organisms 258
 Biogen v. Medeva, case and judgement 117–121
 BioIndustry Association, SmithKline Beecham as Patron 4
 Bioinformatics 316
 cDNA high-density grids, analysis 322
 engineering approach 43
 gene expression profiling and 316
 problems in drug discovery programmes 43
 R&D approach 168–169
 Biological threat, detection systems 254
 BioPartnering Europe (BPE) conference 4
BioPartnering Europe (BPE) (CR) 4
 Biostratum, preclinical studies of anticancer drugs 160
 Biotechnology, patent protection for inventions 117–121
 Biotechnology companies, win-win licensing deals 312
 Biotechnology industry
 collaboration with pharmaceutical industry 72
 innovation 74–75
 Biotech Rumor Mill, web site 2
 Biotransformation
 applications 513–531
 enantioselective reductions 520
 steroids 529–530
 Bis-arylamides 493
 Bis-catechols, HIV integrase inhibitors 490–492
N,N'-Bis-salicylhydrazine 493
 BK channels 391
 Blood pressure, serotonin effect 296
 Blood vessels
 formation 50–51
 see also Angiogenesis
 serotonin effect 296
 BMY14802 519, 520
Borrelia burgdorferi, Phase III trial for vaccine 130
 Bosentan, endothelin-1 receptor antagonist 86
 BQ123, endothelin-1 (ET-1) receptor antagonist 87
 Bradykinin antagonists 163
 Brain, CATNAPs in 36
 Break-even points 367–369
 Breast tumours, epothilones action 87
 Bristol-Myers Squibb
 Award for Distinguished Achievement in Neuroscience Research 456
 Collaboration with Cubist 303
 FDA clearance to market VAGISTAT 160
 research and licensing agreement with Aurora Biosciences 49
 BRL61063 (PDE4 inhibitor) 89, 91, 279
 Bronchial hyper-reactivity, phosphodiesterase 4 (PDE4) inhibitors effect 98–99
 Bronchial smooth muscle, phosphodiesterase 4 (PDE4) inhibitors effect 97–98
 Bronchoconstriction, allergen-induced, phosphodiesterase 4 (PDE4) inhibitors effect 98
 Bronchodilators
 muscarinic M₁ antagonists 343, 344
 phosphodiesterase 4 (PDE4) inhibitors 97–98
 Broxaterol 519, 520
 Brush-border enzymes 151
 Bryolog 362
 Buccal drug delivery 403
 Bulk reagent delivery systems 395–396
Business for Bioscience (CR) 4
 Business process re-engineering 549–550, 553
- C**
 C5a receptor antagonists, nonpeptidic 303
 c7E3 (ReoPro) monoclonal antibody 194
 C1988 (PD134308) 288, 289
 cA2 monoclonal antibody (anti-TNF- α) 275–276, 429
 Caffeic acid phenethyl ester (CAPE) 489, 491
 Caffeine 480
 Caffeoylquinic acid 491, 492
 Calcimimetics 360
 Calcium
 metabolism, changes in ageing 69
 potassium channels activated by 161, 391
 Calcium agonists 303, 360
 Calcium antagonists, *see* Calcium channel blockers
 Calcium channel, voltage-gated, stereoselectivity of drugs 142, 144–145
 Calcium channel blockers
 biocatalysis 524–525
 biotransformation 517, 520
 enantiomers and biotransformation 517
 neuronal 220, 224
 nonstereoselectivity 142
 SNXIII, Phase III trial 121
 Calcium channel openers 303, 360
 Callipeltoside A 79
 Calmodulin, changes in ageing 69
 Calpain inhibitors 220, 224–225
 Cambridge Combinatorial 170–171
 Camptosar, biocatalysis 515, 516
 Cancer
 molecular diagnosis and genetic profiling 310
 therapy, *see* Anticancer agents
 see also specific tumours;
 Tumour
 Cancer Genome Anatomy project (CGAP) 310
 Candidate compounds, selection method 397–398
 Captopril, biocatalysis 514, 515
 Caramiphen 345–346

- Carbapenems
 effective against MRSA 446
 lipophilic 35
- Carbohydrates
 angiogenesis inhibitors 60
 chemoenzymatic synthesis 518–519
 six-membered rings, antiviral nucleosides 238
- Carbonic anhydrase inhibitor 354, 523
- Carbovir 240, 516
- Carcinoid syndrome, serotonergic drugs 297, 299
- Cardiac glycosides 110
- Cardiotonic drugs 110–116
- Cardiovascular disease
 serotonergic drugs 297, 299
 see also Heart failure
- Cardiovascular drugs,
 stereoselectivity 144–146
- Cardiovascular system, serotonin receptors as drug target 294–300
- Carvedilol 115
- Caspases 502
 substrate specificities 502
- CAS Registry numbers 184
- Castanospermine 518
- Catalysts, biologically-derived,
 see Biocatalysis
- Catecholamine absorbing
 proteins (CATNAPs) 36
- Cathepsin D inhibitor library 394
- CATNAPs (catecholamine
 absorbing proteins) 36
- CC1065, DNA binding 304
- CC2137 20–21
- CCK_B/gastrin receptors, as
 therapeutic target 284
- CCK_B/gastrin receptors
 antagonists 79–80, 247,
 283–293, 555
 benzodiazepine derivatives
 286–288
 bicyclic heteroaromatic
 derivatives 290
 dibenzobicyclo[2.2.2]octane
 290
 dipeptoids 288–289
 glutamic acid derivatives
 285–286
 miscellaneous 291–292
 nonpeptide 284–285
 peptic ulcer therapy
 283–293
 pyrazolidinones 289
 therapeutic potential 292
 ureidoacetamides 289–290
 ureidobenzazepines
 290–291
- CD4 cells, monoclonal antibodies 433
- CD18 191, 193
- CD31 198
- CD2345 285, 286
- CD2622 285, 286
- cDNA, full length sequences,
 automated genome
 sequencing 511
- cDNA libraries
 array-based technologies
 315, 316
 arrayed 318
 automated analysis 321–323
 construction 317–318
 gridded, hybridization-based
 analysis 318–321
 high-density grids 318, 322
 large-scale thermocycling
 robots 322
 OligoFingerprinting 319, 321
- CDP571 anti-TNF- α antibodies
 276, 429
- CDP840 [phosphodiesterase
 (PDE4) 4 inhibitor] 91, 95,
 327, 331
- ced-3* and *ced-4* genes 226
- Celecoxib 326, 327, 428, 429
- Cell, senescence, see Senescent
 cells
- Cell adhesion, regulation by
 integrins 189–190
- Cell adhesion molecules (CAMs)
 advances and clinical
 implications 187–199
 drug under development
 192–193
 role in disease states 187–188
- Cell-based assays
 high-throughput screening
 251
 semi-automated for HTS
 503–504
- Cell cultures
 drug absorption models 398
 heterogenous (growth
 potential) 67
 senescence 66–67
- Cell cycle genes, changes in
 senescent cells 70
- Cell growth, p53 action 164
- Cell lines
 immortalized human CNS 504
 senescent, in drug assays 70
- Cell signaling, see Signaling
- CentTNF 429
- Central nervous system
 cell line 504
 drugs, Neuraxis focus 28
 stimulants 162
- Cephalosporins 162
 biocatalysis 527–528
- Ceramide-mediated signaling,
 drug target 558
- Cerebral ischaemia, serotonergic
 drugs 297, 299
- Cerebrus, joint venture with
 Medeval (Neuraxis) 28
- c-fos* 227
 apoptosis mediated by 305
 repression in senescent
 fibroblasts 70
- CGS27023A 432
- Chemokines
 inhibitors 328–329
 membrane-bound with CX₃
 motif 207
- Chemscape Chime 39
- Chicoric acid 491
- Chip technology, see Gene chip
 technology
- Chiral assays 141
- Chirality 138–147
 see also Enantiomers;
 Stereoselectivity
- Chiroscience, alliance with Alcon
 Laboratories 354
- Chloride ion, efflux during
 neutrophil activation 38
- Chloride ion channel, in cystic
 fibrosis 212
- Chloropareillic acid 495
- Chloroquine 489
 resistance 34
- Chlorpromazine 544
- Cholecystokinin 283
 CCK_B receptor, see
 CCK_B/gastrin receptors
- Cholestane glycoside, cytostatic
 123
- Cholesterol
 hydrocortisone synthesis from
 530
 synthesis, inhibitors 249
- Cholesterol lowering agents,
 heterocyclic ureas 123
- ChromaXome Corporation,
 combinatorial biosynthesis
 506
- α -Chymotrypsin 517
- CI988 (cholecystokinin B inhibitor)
 80
- Cidofovir 235, 242
- Cimetidine 145
- Cleavage, small-scale, solid-phase
 reaction analysis 102–103
- 'Cleave-and-analyze' methods,
 NMR 469
- Clinical trials
 cyclic HIV protease inhibitors
 14–16
 Phase I
 MiKasome 452
 SIB1508Y 498
 Phase III
 SNXIII (calcium channel
 blocker) 121
 vaccine against Lyme
 disease 130
- Cloning, phosphodiesterase 4
 (PDE4) 91–93
- Clozapine 480
- CL331002 (Schering-Plough) 47
- c-met proto-oncogene product
 (MET) 53, 57
- CNS cell line, immortalized
 human 504
- Codeine
 ineffectiveness in ethnic
 groups 456
 metabolism 456
- Collaborations 75
 architectural structure of R&D
 200–205
 biotech companies and
 academic institutions
 75–76
 biotech and pharmaceutical
 companies 72

- Mitokor and academics/companies 211
- Collagenase inhibitor 554
- novel inhibitors 81
- COLLAMERS™, preclinical studies 160
- Colon tumours, epothilones action 87
- Colorimetric assays, solid-phase reaction analysis 103
- Combinatorial biosynthesis 505–506
- Combinatorial chemistry
 - antibacterial solution library 556
 - anticancer agents from OBOC libraries 124
 - 1,4-benzodiazepine-2,5-diones 163
 - benzodiazepinediones 304
 - bradykinin antagonists 163
 - Cambridge company 170–171
 - carbohydrate-modified enkephalins 502–503
 - caspase substrate specificities 502
 - cathepsin D inhibitors 394
 - dendrimer supports 81
 - global market 171
 - GP1Ib/IIa antagonists 37, 207–208
 - high-resolution NMR 468–478
 - hydroxystilbene kinase inhibitor 556
 - interleukin-1 β -converting enzyme 304–305
 - laser optical encoding 354
 - lavendustin A 208
 - linker for amidines 447
 - mathematical description 250
 - matrix metalloproteinase inhibitors 37, 216
 - at Mitokor 212
 - molecular diversity and (BR) 177–178
 - natural products 258–259
 - nonpeptide stromelysin inhibitors 447–448
 - novel linkers/strategies and solid-phase organic chemistry 214–217
 - outsourcing companies 307–308
 - patents 37
 - peptidomimetics and 255–256
 - pH-cleavable linker 502
 - platelet fibrinogen receptor antagonists 37, 207–208
 - polymers 394
 - protein phosphatase inhibitors 208–209
 - purine synthesis 208
 - rational drug design 81
 - SLE inhibitors 163
 - solid-phase chemistry monitoring by FTIR 37
 - solid-phase synthesis of penicillins 556–557
 - spatially arrayed mixture technology 305
 - spiroindolines 250
 - water-soluble synthetic receptors 447
 - xanthines as library scaffold 354
 - see also* Combinatorial synthesis
- Combinatorial libraries 357
 - $\alpha_v\beta_3$ integrin antagonists 394
 - antibacterial solution 556
 - book review 177–178
 - cathepsin D inhibitors 394
 - companies generating 308
 - computational screening 229–234
 - hydroxystilbene kinase inhibitor 556
 - on Internet 171
 - MMP inhibitors 216
 - one bead–one compound (OBOC), anticancer agents 124
 - pH-cleavable linker 502
 - virtual 39, 354
 - xanthines as scaffold 354
 - see also* Compound libraries
- Combinatorial synthesis
 - automated, liquid handling 41
 - solid-phase, analytical techniques 102–189
 - see also* Combinatorial chemistry; Solid-phase chemistry
- Combinatorial technology, patents 37
- Communication, R&D success 204–205
- Comparative molecular field analysis (CoMFA) 457, 462
- Comparative molecular similarity indices analysis (CoMSIA) 464
- Compensating mechanisms, R&D costs and economic constraints 371
- Complement, C5a receptor antagonists 303
- Complexation constants, late-stage candidates 424
- Compound libraries
 - new strategies (conference) 214
 - virtual molecules on Internet 39
 - see also* Combinatorial libraries
- Computational microscope 132
- Computer-aided drug design, multicopy sampling 229–234
- Computers/computing
 - break-even points calculation 367–369
 - genome sequencing and analysis 511
 - molecular shape analysis based on 132–137
 - screening of combinatorial libraries 229–234
 - software for molecular modelling on Internet 40
 - strategies for lead discovery 168–169
 - technologies for information extraction 43–45
 - see also* Information technology
- Congestive heart failure
 - inotropic therapy 110
 - troponin C therapy 508
- Consortia, of small companies 203
- Contract research organization (CRO) 201
- Corticotropin-releasing factor (CRF) 80
- CRF₁ receptor antagonists 80
- Cosalane 494, 495
- Cosmid DNA 258
- Coulomb interactions 463
- Coumarins 494
 - HIV integrase inhibition 493, 494
- Coumermycin A1 493
- Cowpox virus, protein (CrmA) 227
- COX-1 326
- COX-2 325–326
 - selective inhibitors 122, 393, 501
 - in arthritis 428
- CP2458 (bradykinin antagonist) 163
- CP80633 [phosphodiesterase 4 (PDE4) inhibitor] 91
- CP122288 298
- CR2345 (CCK_B/gastrin receptor antagonist) 286, 291–292
- Creativity, in pharmaceutical companies 550, 552
- Credit-card sized chips 253–254, 306
- Crixivan 140
- Crown ethers 452
- Cryptosporidium*, apicidin activity against histone deacetylase 82
- CSAIDs 35
- CT1731 (phosphodiesterase 4 inhibitor) 91, 95
- Cubist, collaboration with Bristol-Myers Squibb 303
- Curcumin 490
- Cyclic AMP (cAMP)
 - chloride ion channel activation 212
 - compounds mimicking effect on CFTR protein 212
 - elevated, effects 95–96
 - hydrolysis by phosphodiesterase 4 (PDE4) enzymes 89

- phosphodiesterase inhibitors
 - action 278
- Cyclic depsipeptide 79
- Cyclic HIV protease inhibitors 6–18, 362
- Cyclic ureas
 - analogues, comparison 8
 - design 9
 - five-membered ring 13–14
 - HIV protease inhibitors 6–18, 362
 - seven-membered ring 10–11
- Cyclin-dependent kinase (CDK)
 - inhibitors, changes in senescent cells 70
- Cyclization, bioreversible 153–154
- Cyclohexane partitioning,
 - cytochrome P450 isoenzymes 481, 482
- Cyclolinopeptide B 391
- Cyclomarin A 258
- Cyclooxygenase 122, 248
 - COX-2, *see* COX-2
 - inhibitors 325–326
- Cyclosporin A 434
- Cydot system 403
- CYP2D6, *see* Cytochrome P450 isoenzymes
- Cystic fibrosis 207, 212
 - AAV-CFTR gene therapy trials 5
 - chloride transporter channel 452
 - drug target 207
 - new therapies 212
- Cystic fibrosis transmembrane conductance regulator (CFTR) 207, 212
 - gene mutations 212
 - gene therapy 5
 - mechanism of action 212
- Cytochrome P450 isoenzymes 406
 - active site structure 407–408
- CYP1A2 408–409
 - inhibitors 480–481
 - properties and substrates 480–481
- CYP2A6 413
- CYP2C9 409–410
 - inhibitors 481
 - properties and substrates 481–482
- CYP2C19, properties and substrates 482
- CYP2D6 410–411
 - codeine metabolism 456
 - drug metabolism 485
 - ethnic variations 456
 - inhibitors 483
 - lipophilicity 483
 - properties and substrates 483
- CYP2E1 412–413
 - properties and substrates 484
- CYP3A4 411–412
 - drug metabolism 484, 485
- properties and substrates 483–484
 - drug design and 484–486
 - drug metabolism and strategies to overcome 485
 - properties and substrates 406–414, 479–486
 - substrate/selectivity rules 485
- Cytokine(s), in inflammation 329–330
- Cytokine inhibition 329–330, 429–432
 - antagonist of cytokine effects 429–430
 - convertase inhibitors 431
 - signaling inhibition 430–431
 - synthesis inhibition 430
- Cytokine suppressive anti-inflammatory drugs (CSAIDs) 35
- Cytokine suppressive drugs 35
- Cytotoxic natural products 79
- D**
- L-D4A 238
- D5410 432
- DAMP analogues 346
- DAPI 490
- Databases
 - chemical (SpaceCrunch) 169
 - estimated future size and approach 43
 - LifeSeq® 310
 - object relational 44
 - pharmaceutical competitor tracking 179–186
 - see also* Information technology
- Data management, effective decision making in companies 552–553
- Datamonitor, yearbooks 121
- DAU5750 346
- Death receptor-4 (DR4) 448
- 3-Deazaneplanocin A 236
- Decision making, in pharmaceutical companies 552–553
- DELFI chelate 376–377
- Denbufylline (BRL30892) 91
- Dendrimer supports 81
- 2'-Deoxyguanosine, analogue 161
- Deoxymannojirimycin 518
- Deoxynojirimycin 518
 - derivatives 248
- Depsides 495
- Depsidones 495
- Design, *see* Drug design
- Desmopressin, uptake of prodrug 152
- Development time 1, 531
- Dexmedetomidine 38
- Dextran sulphate 496
- Diabetes mellitus
 - complications, drugs for 450
- see also* Non-insulin-dependent diabetes mellitus (NIDDM)
- Diacerein 430
- Diagnostic tests
 - Alzheimer's disease 212
 - homogeneous and heterogeneous assays 374
- Diaminopyridines 556
- 1,2-Diaryl-cyclobutenes 122
- 1,2-Diarylimidazoles 393
- 1,5-Diarylpyrazones 122
- 1,2-Diarylpyrroles 393
- Diarylsulfones 497
- Diarylsulphonylureas 80
- Diazeniumdiolates, nitric oxide release 3
- Diazepam 482
- Dibenzobicyclo[2.2.2]octane 290
- Dicaffeoylquinic acid 491
- Diclofenac 481
- Didanosine 236
- L-Dideoxycytosine 238
- DiGeorge syndrome 511
- Digitalis 110
 - mechanism of inotropic and toxic actions 112–113
 - receptor (Na⁺/K⁺-ATPase) 111, 112
 - toxicity 111
- Digitalis derivatives 113–114
 - inotropic selectivity 110–116
 - replacements/alternatives 110–116
 - therapeutic range 114–115
- Digoxin, in heart failure 110
- Dihydropyridines, stereoselectivity 144, 145
- Dihydroxynaphthaquinone 489
- Diltiazem, biocatalysis 524–525
- 3-Dimensional Pharmaceuticals, thrombin inhibitors 311
- Dimerization 254
- Dipeptoids
 - analogues 291
 - CCK_B/gastrin receptor antagonists 288–289
- Discounted cash-flow model 367–369
- Disease-modifying antirheumatic drugs (DMARDs) 427
- Disintegrin 353
- Disopyramide, stereoselectivity 141
- Dispacamides 555
- Dissociation constants 417–418
 - preclinical/clinical candidates 422–423
- Dissolution rate constants 420
- Distamycin 490
- Diversity, *see* Biodiversity; Molecular diversity
- DMP323 9
 - pharmacokinetics 16
- DMP450 9, 83–84
 - pharmacokinetics 15, 16

- DNA
 antiviral nucleosides 235–242
 binders, as HIV integrase inhibitors 489–490
 damage, neuronal cells 221
 extraction from marine sediments 259
 synthesis, in DNA chips 253–254
 synthesis inhibitors, viral 238
- DNA vaccines
 intranasal delivery 404
 oral 404
- Docetaxel 87
- L-DOPA, biocatalysis 526
- Dopamine, oxidized, damage/diseases due to 36
- Dopamine receptors 333–340
 agonists 338
 antagonists 338
 D₁-like agents 335–336, 338
 D₂-like agents 336–339
 antagonists 336–339
- D₃
 agents selective for 337, 339
 antagonists 500–501
- D₄ 206
 agents selective for 337, 339, 353
 agonists 499
 ligands 362–363
 selective antagonists 206, 362, 392, 500–501
 discovery 334–335
 molecular biology 335
 selective pharmacological agents 335–340
 subtypes 334
- Dopaminergic agents 333–340
- Dopaminergic Allelic Profiling Program 311
- Dopaminergic systems 36
- Doxorubicin 489
- Doxycycline 432
- Drosophila melanogaster*, phosphodiesterase 4 (PDE4) cloning 91
- Drug absorption
 cell culture models 398
 QSAR and 3D QSAR application 538–539
- Drug Alerts 183
- Drug assays, senescent cell line use 70
- Drug delivery
 changes in senescence and ageing 70
 oral and mucosal 402–404
- Drug design
 cyclic HIV protease inhibitors 6–18
 peptidomimetic drugs 165–167
 phosphodiesterase 4 (PDE4) inhibitors 89–101
 see also Rational drug design
- Drug development
 acceleration and company improvement 548
- backup and follow-up strategy 443
- drug discovery interface 436–444
- pharmacoeconomics 438–440
- project failure 442
- risk management 442
- selection of project 440–442
- target product profile 436–438
- time course 1, 531
- 'want' and 'must' criteria for performance 437
- Drug discovery
 acceleration 357–358
 importance of 548–549
 improvements for companies 547–553
 alliance, monitoring performance and quality 29–33
 automation benefits 40–43
 bottlenecks 357
 combinatorial libraries and (BR) 177–178
 development interface management 436–444
 teams 443
 see also Drug development
- drug metabolism integration, HPLC-API/MS/MS role 532–537
- genome sequencing role 510
- genomic sciences 77
- IT-based software 44
- Java-based tools 44
- molecular shape analysis 132–133
- senescent cell line use 70
- time course 531
- Drug distribution, QSAR and 3D QSAR application 538–539
- Drug metabolism
 integration into drug discovery, HPLC-API/MS/MS role 532–537
 in vitro evaluation 397
 metabolite identification by HPLC-API/MS/MS 534–536
 microbial models 397
- Duocarmycins, DNA binding 304
- Dupont Merck Pharmaceuticals, collaboration deal 354
- Dye terminators, large 510–511
- DYLOMMS 461
- Dysiherbaine 353
- E**
- Eclampsia of pregnancy, serotonergic drugs 297, 299
- Economics
 constraints in pharmaceutical companies 365–372
 pharmacoeconomics 438–440
- Eczema, γ -linolenic acid product 450
- Efamol Nutrition 449
- Efflux systems, intestinal 151
- Elastase, neutrophil, inhibitors 162
- Elastase inhibitors 432
- Elderly
 adverse drug reactions 65
 diseases 64–66
- Electron density 132–133
 images 134–135
- Electronic charge cloud 132
- Eletriptan 298, 362, 363
- Elipten 519, 520
- Emerging drugs (BR) 313
- Emerging Therapeutic Targets 398
- Enantiomeric interactions 127
- Enantiomers 139
 lipase-catalyzed resolution 514–516
 non-racemic mixtures 127
 NSAIDs 514
 nucleosides 237
 prochiral intermediates 516–518
 racemates versus 127, 139
 side effects 140
 see also Biocatalysis; Stereoselectivity
- Enantiomorphic composition, determination 416–417
- Enantiopure drugs 140, 141
 sales 140
- Enantioselective reductions, ketones 519–520
- Enbrel 429
- Encapsulation 258
- Encryption methods 205
- Endocytosis 150
- Endo puckering 239
- Endothelin 85–87
- Endothelins: New Therapeutic Opportunities* (CR) 85
- Endothelin-1 (ET-1) 85
 big (big ET-1) 85
 knockout mice 86
 pathophysiological role 86–87
 receptors, see Endothelin receptors
- Endothelin-3 (ET-3) 86
- Endothelin-converting enzyme (ECE) 85
 inhibitors 86
- Endothelin receptors
 antagonists 85–86, 500
 orally active 554
 ET_A, antagonists 249, 392, 500, 554
 ET_B, antagonists 500, 554
 subtypes 85
- Endothelium-derived contracting factors 85
- Engineering, approach to bioinformatics 43
- Enkephalins, carbohydrate-modified 502–503
- Enoxacin 480

- Enterococcus faecalis*, antibiotic resistance 47
- Enterococcus faecium*, antibiotic resistance 47
- Enzymatic Mutation Detection™ 310
- Enzymes
- 3D QSARs of ligands 540
 - inhibitors, QSAR and 3D QSAR application 539–540
 - QSARs of ligands 539
 - regioselectivity 518
- Eosinophils, $\alpha_4\beta_1$ integrin expression 191
- L-Ephedrine, biocatalysis 526–527
- Epidermal growth factor (EGF) receptor 53, 56–57
- Epilepsy
- neuropeptide-Y₅-like receptor 504
 - new drug target 504
- Epithelial cell kinase (ECK) 53, 56
- Epothilones 87–88
- Epstein–Barr virus, replication inhibitors 238
- Erythema nodosum leprosum 277
- Erythromycin 483, 484
- analogues 506
- Escherichia coli*, enterotoxigenic (ETEC) 404
- Escherichia coli* K12, genome sequencing 510
- E-selectin 188
- Ethics, in drug research (BR) 49
- Eugenol 244
- European Bioinformatics Institute 168
- Europium cryptate 377
- Evening primrose oil 449
- Evernimicin 47–48, 257, 521
- EVOTEC BioSystems, ultra-high-throughput screening 209
- Excitatory amino acids (EAA)
- receptors 35, 222–223
 - release inhibitors 220, 223–224
 - role in neuronal cell death 222
- Excitotoxicity 222
- Exclusivity, in compound classes 1
- Expressed sequence tags (ESTs) 510
- Extracellular matrix proteins, advances and clinical implications 187–199
- F**
- Famciclovir 235
- Farnesyl protein transferase, inhibitors 123, 499
- Feeding, blockade by
- neuropeptide Y₁ receptor antagonists 23
- FEMSTAT, FDA approval 130
- Fermentation–biotransformation 520
- Fertilin 353
- Fertility, male, control 500
- Fertilization, inhibitor 353
- Fibrinogen 189
- Fibroblast growth factor (FGF)
- antibodies 58
 - basic, *see* Basic fibroblast growth factor (bFGF)
 - receptor 53, 57
- Fibroblast growth factor receptor 1 (FGFR1), compounds binding 355
- Fibroblasts
- cellular hypothesis of ageing 66–67
 - in vitro* growth 67
 - senescent 66
 - changes in 69, 70
- Fibronectin 190, 198
- FIPCO (fully integrated pharmaceutical company) 200
- Flavones 489
- Flavonoids, calcium channel openers 303
- Flecainide 486
- Flk-1 53, 55–56, 58
- antibodies 60
 - inhibitors 60
- Flt-1 53, 55–56
- soluble receptor 60
- Fluorescence-based assays, high-throughput screening 156–160
- Fluorescence correlation spectroscopy, high-throughput screening 159
- Fluorescence imaging, hardware for cell-based screening 159–160
- Fluorescence polarization (FP) 375
- high-throughput screening 158
- Fluorescence resonance energy transfer (FRET) 374–375
- high-throughput screening 156–157
 - time-resolved 378
- Fluorescent screening, ultra-high-throughput screening 49
- L-5-Fluoro-3TC 238
- L-Fluorodideoxycytosine 238
- Fluorometry 374, 375–381
- phase-resolved 375
 - time-resolved, *see* Time-resolved fluorometry
- 4-Fluorophenyl analogue 80
- Fluorophores 158
- Fluoroquinolones
- for Gram-positive bacteria 48
 - new agents 49
- FluorRx, licensing deal 393
- Flurbiprofen 513–514
- L-FMAU 238
- Fosphenytoin 224
- Fostriecin (C1920), absolute stereochemistry 248
- Fourier transform infrared (FTIR) spectroscopy
- single-bead 106–107
 - solid-phase reaction analysis 37, 106–107
- Free radicals 225
- inhibitors 220, 225–226
 - spin trapping reagent 226
- Free Wilson analysis 458–459
- FTIR, *see* Fourier transform infrared (FTIR) spectroscopy
- Fungi
- transporters 510
 - see also* Antifungal agents
- Fuzzy logic 43, 45
- Fuzzy molecular electron density fragments 132–137
- G**
- GABA receptors, GABA_A and GABA_B (BR) 131
- β -Galactosidase, assay for cell senescence 68
- Gallopamil 145, 146
- Ganciclovir 242
- GAP31 497
- Garcinal 555
- Garcinoic acid 555
- Gastric acid secretion, inhibitors 247
- Gastrin 283
- receptors, *see* CCK_B/gastrin receptors
- Gastrointestinal tract
- drug delivery and absorption 402
 - M₁ receptors 342–343
- GBNet (Global Biopartnering Network) 4
- Gelatinase A 432
- drug target 396
- Gene(s)
- functional analysis, array-based technology 323
 - metabolism of analgesics and 456
 - orphan 510
- Gene chips 253–254, 306, 557
- Gene chip technology 511, 557
- companies involved 557–558
 - glass wafers (gene chips) 557
- Gene cloning, phosphodiesterase 4 (PDE4) 91–93
- Gene expression
- changes in senescence 69–70
 - neuronal excitation links 227
 - profiling, array-based technologies 315–324
- Genetic engineering
- Biogen v. Medeva patent case and judgement 117–121
 - natural products 259
- Genetic imprinting 510
- Genetic polymorphisms, identification 311
- Genetic profiling 310–311
- array-based technologies 315–324

- clinical applications 310–311
- Genistein 207
- Genome
 - Human, mapping 168
 - IT and automation 511
 - sequencing, developments (CR) 510–511
- Genomic databanks 77
- Genomics 510
 - drug discovery routes 77
 - drug targets from 168
 - patient selectivity and economic constraints 365
 - processing modules 454
- Genome Sequencing and Analysis Conference* (CR) 510–511
- Gerontology 64–71
- GI129471 (MMP inhibitor) 279
- Glass wafers 557
 - see also* Gene chip technology
- Glaucoma, treatment 523
- Glaxo Wellcome 200
 - drug development targets 548
 - HIV protease inhibitor Phase II study 160
 - R2 system 209
- Glial cells, injury/death 219
- Glipizide, biocatalysis 525, 526
- Global Biopartnering Network (GBNet) 4
- Glucagon-like peptide-1 (GLP-1) 128
 - oral delivery 403
- α -Glucosidase inhibitors 248
- Glucose, in D-myo-inositol (1,4,5)-trisphosphate analogue 214
- α -Glucosidase gene, adeno-associated virus (AAV) as vector 5
- Glucuronic acid, enkephalin derivative synthesis 502
- Glutamate
 - metabotropic receptors 223
 - release inhibitors 223–224
- Glutamic acid derivatives, CCK_B/gastrin receptors antagonism 285–286
- Glutamine piperazinyll scaffold 255–256
- Glycine re-uptake inhibitors 303
- Glycopeptides, under development 48
- Glycoside macrolide, cytotoxic 79
- Glycylglycines 47
- Gomisin-G 555
- GP1515 (adenosine agonist) 280
- GPIIb/IIIa antagonists, *see* Platelet $\alpha_{IIb}\beta_3$ (GPIIb-IIIa) receptor antagonists
- G-protein
 - dopamine receptor interaction 335
 - receptors, ligand design 254–255
- G-protein-coupled receptors (GPCR) 329
- Graft-versus-host disease (GVHD) 277
- Gram-negative bacteria, antibacterial agents 162
- Gram-positive bacteria
 - antibiotic resistance 47–49
 - new antibiotics from natural products 257–258
- GRI-1 and GRI-2 303
- Growth factor receptors
 - changes in senescent cells 69
 - see also* Receptor tyrosine kinases (RTKs)
- Growth factors, neuroprotective 220, 226
- Growth hormone, secretagogues 301–302
- Guanosine quartets, as HIV integrase inhibitors 488–489
- H**
- H₂ receptor analogues, with CCK_B receptor antagonists 291
- Hansch analysis 459–460
- Hawaiian plants, source of novel drugs 177
- HCKFWW, HIV integrase inhibitor 496
- Headache, phosphodiesterase 4 (PDE4) inhibitors inducing 99
- Heart failure
 - inotropic therapy 110
 - need for selective inotropes 111
- Helicobacter pylori*, eradication, CCK_B/gastrin receptors antagonists 286, 292–293
- Helix–helix interactions 254
- Hepatitis B virus
 - Biogen v. Medeva patent case and judgement 118–121
 - inhibitors, new natural products 555
 - novel analogue of 2'-deoxyguanosine 161
 - vaccine, patent case 118
- Hepatocyte growth factor/scatter factor (HGF/SF) 57
- receptor (MET) 53, 57
- Herpes simplex virus 1 (HSV1), ubiquitin-specific protease control of gene expression 250
- Herpes simplex virus 2 (HSV2), antiviral nucleosides 236
- Heterocyclic ureas, hypocholesterolaemic agents 123
- Heterogeneous assays 374
- High-performance liquid chromatography, *see* HPLC
- High-resolution NMR 468–478
- High-throughput NMR spectroscopy 474–477
- High-throughput screening 384–wells
- assay miniaturization 503
- biochemical assays on R2 robotic system 503
- liquid-handling systems 395
- 1536 well plates 355, 504
- automated
 - development (case history) 385–390
 - strategies (BR) 88
- automated pipetting devices 395
- automation 40–43, 209
- automation approaches 209
- automation requirements 378–381
- bulk reagent delivery systems 395–396
- cell-based assays 251, 503–504
- competitive assays 374
- false positives 382–384
- fluorescence-based assay technologies 156–160
- gene chip technology 557
- glass wafers 557
- high-density plates (1536-well) 355, 504
- inkjet technology 396
- integrated customer-specific systems 209
- integrated off-the-shelf systems 209
- in vitro*/biochemical assays 251
- liquid-handling systems 395
- miniaturization 306, 381, 503
- nanolitre dispensing 396
- origin and development 361
- piezoelectric technology 396
- project life cycles 389–390
- R2 system (Glaxo Wellcome) 209
- reactive compounds 382–384
- remote sensing technologies 381
- robotics 209, 385
- robotic sample processors 395
- robotic systems 251, 379
- semi-automated cell-based assay 503–504
- Society for Biomolecular Screening 361
- time-resolved fluorometry 156–157, 380–381
- ultra-HTS 49, 209
- workstations 209
- Histone deacetylase 82
- HIV-1
 - antiviral nucleosides 237
 - gp41 dimer, disruption 254
 - inhibitors, new natural products 555
 - integrase 487
 - inhibitors, *see* HIV-1 integrase inhibitors
 - Rev response element (RRE) 555

- thalidomide use 277
- vaccine delivery 404
- HIV-1 integrase inhibitors 487–488
 - DNA binders 489–490
 - hydroxylated aromatics (catechol-containing) 490–492
 - non-catechol containing aromatics 492–496
 - nucleotides and guanosine quartets 488–489
 - peptides and peptidomimetics 496–497
- HIV-1 protease 6, 262
 - chirality 139
 - inhibitor complexes 8
- HIV-1 protease inhibitors 261–272
 - 141W94 (VX478) 160, 270
 - Phase II study 160
 - bicyclic 79
 - clinical results 268–270
 - currently approved agents 83, 261
 - cyclic 362
 - bioavailability and trials 14–16
 - displacement of active site structural water molecule 6–18
 - design considerations 262
 - lead identification 262–270
 - linear, cyclization 10, 12
 - new agents 83–84
 - renin inhibitors 83, 263
 - resistance 270–271
 - symmetrization 264
- HMG-CoA reductase inhibitor, biocatalysis 515, 516
- Homocysteine, solid-phase synthesis 214
- Homogeneous assays 374
- Hormones, changes in senescent cells and ageing 69
- House of Lords, Biogen v. Medeva case 117–121
- HPLC, single-bead encoded libraries 216
- HPLC-API/MS/MS
 - drug metabolism integration into drug discovery 532–537
 - multiple analyses 536–537
- Human cytomegalovirus (HCMV) 241
- Human Genome Mapping project 168
- Human immunodeficiency virus, *see* HIV-1
- Humanized antibodies
 - anti- $\alpha_3\beta_3$ antibody (LM609) 60
 - to TNF- α 275–276
- Human serum albumin, uptake in senescent cells 69
- Hutchinson–Gilford progeria 68
- Hydrazides 493
- Hydrocortisone, biotransformation 530
- Hydrolytic enzymes, prochiral intermediates 517
- Hydroperoxyeicosatetraenoic acid (HPETE) 448
- Hydroxamic acids 37, 216
- 4-Hydroxycoumarin 493
- Hydroxylated aromatics, HIV integrase inhibitors 490–492
- Hydroxystilbene kinase inhibitor, library 556
- 5-Hydroxytryptamine (5-HT) receptors
 - 5-HT₃ receptor antagonists 206
 - cardiovascular responses mediated by 295–296
 - cardiovascular targets 294–300
 - classification/nomenclature 294–295
 - drugs, therapeutic uses 297–299
 - in migraine 296–298
- Hygroscopicity 418–419
- Hypertension
 - endothelin role 87
 - neuropeptide Y₁ receptor antagonist action 23
 - serotonergic drugs 297, 298–299
 - see also* Antihypertensive agents
- Hypocholesterolaemic agents, heterocyclic ureas 123
- Hypoglycaemic agents, oral biocatalysis 525, 526
 - α -glucohydrolase inhibitors 248
- Hypotension
 - A₃ adenosine receptors 35
 - serotonin effect 296
- I**
- Ibuprofen 481, 513–514
- ICAM-1
 - antibodies 433
 - expression in atherosclerotic plaques 198
- Idebenone 226
- IJL BioSystems, licensing deal 393
- Imaging compounds, muscarinic M₁ antagonist 348–349
- Imipramine 482, 486, 544
- Immune response, to oral vaccination 402–403
- Immunoglobulins 197–198
- Immunomodulation
 - in arthritis 432–434
 - drug targets 325–332
- Immunostimulants, novel 555–556
- Immunosuppression, in arthritis 432–434
- Immunosuppressive agents, cyclic nonapeptide 391
- Indinavir 83, 261
 - clinical results 269
 - discovery/design 265–267
- pharmacokinetics 15
- Inflammation
 - A₃ adenosine receptors 35
 - drug targets 325–332
 - phosphodiesterase 4 (PDE4) action 89
- Inflammatory cells, influx, phosphodiesterase 4 (PDE4) inhibitors effect 98–99
- Inflammatory diseases, VCAM-1 and ICAM-1 expression 198
- Influenza coat protein, sialic acid binding site 231
- Information, estimated future database sizes 43
- Information extraction, technologies 43–45
- Information resources, in pharmaceutical competitor tracking 179–186
- Information technology
 - conference 167–169
 - genome sequencing 511
 - R&D success 205
 - software for drug discovery 44
 - see also* Computers/computing; Databases
- InfoTech Pharma 167–169
 - 1998 169
- InfoTech Pharma '97 (CR) 167–169
- Infrared spectroscopy, solid-phase reaction analysis 106–107
- Inkjet technology 396
- Innovation 75
 - in biotech industry 74–75
 - deficit in pharmaceutical industry 74
 - in pharmaceutical industry 72–78
 - stimulation in companies 551, 552
 - strategy 75–77
- Innovation gap 312
- Innovative discovery, process 551
- Innovex, acquisition by Quintiles 45
- Inositol monophosphatase 214
- Inositol polyphosphate cascade, control 214
- D-myo-Inositol-(1,4,5)-trisphosphate 214
- Inotropic therapy 110
 - inotropy/toxicity-linked isoforms of Na⁺/K⁺-ATPase 113–114
 - need for selective agents 111
 - new digitalis derivatives 110–116
 - selective 113–115
 - see also* Digitalis
- Insulin
 - resistance 128

- animal models 129
- TNF- α role 128
- sensitizers 128
- Insulin-like growth factor-1 (IGF-1) 58
- Integrelin 195
- Integrins 189–197
 - α_4 190–191
 - $\alpha_4\beta_1$ 191
 - $\alpha_{IIb}\beta_3$ 193–196
 - antagonist 194
 - c7E3 monoclonal antibody 194, 196
 - α_v , osteopontin interaction 198
 - $\alpha_v\beta_3$ 196–197, 501
 - antagonist library 394
 - antagonists 196–197, 501
 - CD31 interaction 198
 - β_1 191
 - β_2 191, 193
 - β_3 193–196, 196–197
 - cell signaling 125
 - cell adhesion and signaling regulation 125, 189–190
 - epithelial 197
 - matrix interactions 197
- Interferon- α , angiogenic inhibitor 60
- Interferon- γ , agents to enhance activity 556
- Interleukin 1 β 330
- Interleukin-1 β -converting enzyme (ICE) 226–227, 330, 431
 - inhibitors 431
 - pyridone-based
 - peptidomimetic 391
 - substrate specificities 304–305
- Interleukin 8 (IL-8) 328–329
- Internet
 - combinatorial libraries 171
 - 3D applications and VRML 39
 - Global Biopartnering Network (GBNet) 4
 - microplate suppliers 174
 - pharmaceutical R&D strategies 167–169
 - web sites 2
 - InfoTech Pharma '98 conference 169
- International Symposium on Laboratory Automation and Robotics* (CR) 40
- Interoperability 168
- Intestinal epithelial cells 149–150
- Intestinal tract
 - absorption of peptides 148–155
 - biochemical barrier 150–151
 - efflux systems 151
 - physical barrier 148–149, 150
 - uptake of prodrugs 152
- Intracellular kinases, inhibitors 331
- Inventive concept, definitions 118, 119
- Inventors, biotechnology patents and 118
- Investigational New Drug (IND) 1
- In vitro* assays, high-throughput screening 251
- In vitro* growth, fibroblasts 67
- In vitro* models, in drug development programme 397–398
- Ion channels
 - artificial 452
 - chirality of drug actions 142–145
 - ligands, 3D QSARs 540
 - see also* Calcium channel; Potassium channel
- Ipratropium bromide 342, 344
- IRORI Quantum Microchemistry, collaboration 354
- Irritable bowel syndrome, muscarinic analgesics 247
- ISIS2302 433
- 2-Isocephems 162
- J**
- Java-based tools 168
- drug discovery 44
- K**
- Kainate receptors 222, 223
 - antagonists 223
- Kainic acid-induced seizures 504
- Ketoconazole 483, 484
- Ketones, enantioselective reductions 519–520
- Ketoprofen 513–514
- Ketorolac 513–514
- α -Ketothiazole derivatives 249
- Kissei Pharmaceutical Company, HIV protease inhibitor Phase II study 160
- Knowledge tree, drug information files 180
- Kosan Bioscience, combinatorial biosynthesis 505–506
- Kulolide 79
- L**
- L293111 326, 327
- L365260 287
- L709049 430
- L743872 (antifungal agent) 258
- Labetol, stereoselectivity 141
- β -Lactamases 446
- Lactams, enantioselective hydrolysis 516
- Lamivudine 236
- biocatalysis 515, 516
- Lanthanide chelate excitation (LANCE) technology 157–158
- Lanthanide chelates 376
- Lanthanides 376
- Large dye terminators 510–511
- Laser optical encoding 354
- Lavendustin A, solid-phase synthesis 208
- Lead compound
 - antiviral nucleosides 238
 - identification, accelerating 549
 - sources, advantages/disadvantages 549
- Lead discovery
 - advanced computing strategies 168–169
 - libraries 307–308
- Lead optimization 307
 - libraries 308
 - MMP inhibitors 216
- Leflunomide 433–434
- Lenercept 429
- Lennard-Jones potential 463
- Leu-enkephalin, electron density images 137
- Leukaemia
 - cytostatic cholestane glycoside 123
 - kulolide activity against 79
- Leukocytes
 - inflammatory, phosphodiesterase 4 (PDE4) action 89
 - migration 198
 - recruitment, selectin-integrin models 197
- Leukotriene(s)
 - biosynthetic pathway 326
 - modulators 326–328
- Leukotriene B₄ (LTB₄) 326
 - inhibitors 326
 - intracellular receptor 82
 - receptor antagonists 248, 303, 554–555
- Leukotriene D₄ antagonist, enantiomer synthesis 517–518
- Lexitropsins 490
- LFA-1 193
- Libraries
 - cDNA, *see* cDNA libraries
 - 'privileged structure' 214–215, 307–308
 - single-bead encoded 215–216
 - solid-phase, generation and analytical techniques 102–189
 - see also* Combinatorial libraries
- Licensing, win-win deals 312
- Lichen acids 492
- Lidocaine 486
- Lifespans 64
- Ligands
 - binding site mapping, multicopy sampling 230–231
 - design, multicopy sampling and 229–234
 - full-flexible docking 231–232
 - for peptide receptors 38
- Lignanoides 490
- Lignans 555
- Linearmycin A and B 35
- Linker molecules
 - for amidines 447

- 'clean-break' 215
 - for hydroxamate generation 37
 - pH-cleavable 502
 - REM resin 216
 - γ -Linolenic acid, products based on 450
 - Lion Pharmaceuticals, launched 312
 - Lipase
 - prochiral selectivity 517–518
 - reactions catalyzed by, drug preparation 514–516
 - Lipid-based therapeutics 449–450
 - Lipid peroxidation, inhibitor 225
 - Lipophilic agents, kappa opioid agonist 248
 - Lipophilic carbapenems 35
 - Lipophilicity of molecules 150, 483
 - Lipopolysaccharide, *MUC2* gene activation 207
 - Liposomes, DNA, intranasal delivery 404
 - 5-Lipoxygenase activating protein (FLAP), inhibitors 326
 - 5-Lipoxygenase inhibitors
 - 248–249, 326
 - thiophene-2-alkylsulphonamides 352
 - 15-Lipoxygenase, newly discovered 448
 - Liquid handling systems
 - 384 wells in HTS systems 395
 - for automated combinatorial synthesis 41
 - Lithium, manic depression 214
 - Lobucavir 242
 - Local anaesthetics, RAC421 143
 - Loracarbef, synthesis 529
 - Lorglumide 284, 285
 - L-selectin 188
 - immune response to oral vaccination 402
 - LTB₄, see Leukotriene B₄ (LTB₄)
 - LTk63 403
 - Lubeluzole 224
 - Lung, peptide absorption 402
 - LY246348 289
 - LY288513 289
 - LY300164, biocatalysis 522–523
 - LY333328 47, 48
 - LY334370 298
 - Lyme disease, vaccine Phase III trial 130
- M**
- M₁ toxin 348
 - Mac-1 193
 - Macromolecular quantum chemistry 132–137
 - Macrosol™ 402
 - MAdCAM-1 190
 - Magic angle spinning (MAS) NMR 104–105, 470–474
 - 'Magic bullets' 124
 - peptides 124–125
 - Major histocompatibility complex, full-flexible ligand docking with multicopy sampling 231
 - MAK 195F anti-TNF- α antibody 276
 - Malaria, novel drugs against 34
 - Manic depression, second messenger molecule in 214
 - MAP30 497
 - MAP kinase 431
 - Marimastat 61, 216, 327, 328
 - Marine organisms, natural product diversity 258
 - Market penetration 370
 - Market sizes 368
 - Mass spectrometry
 - HPLC-API/MS/MS 532–537
 - solid-phase reaction analysis 107–108
 - Mast cell degranulation, A₃ adenosine receptors 35
 - Mastoparan 497
 - Mathematical description, combinatorial chemistry 250
 - Matrix metalloproteinases (MMPs) 279–280, 302, 432
 - antiarthritic drugs 432
 - collagenase inhibitor 554
 - inhibitors 37, 216, 279–280, 328
 - novel 81, 302–303
 - TNF- α inhibition 279–280, 431, 432
 - MMP-2 (gelatinase A) 396
 - MB-OXTP 345
 - McNA343 analogues 347
 - MDL28618 515, 516
 - MDL74019DG 348
 - MDL201112 (adenosine agonist) 280
 - Medeva
 - joint venture with Cerebrus (Neuraxis) 28
 - judgement in Biogen v. Medeva case 117–121
 - Melanocortin-4 receptor 129
 - Melanocortin agonists 255
 - Memory
 - enhancer projects 185
 - muscarinic antagonists effect 345
 - (S)-Mephenytoin 482
 - (R)-Mephobarbital 482
 - Merck, information technology in R&D strategy 167
 - Metabolites
 - identification by HPLC-API/MS/MS 534–536
 - see also Drug metabolism
 - Metabotropic glutamate receptors 223
 - (M)-Methanocarpa T 239
 - Methicillin-resistant *Staphylococcus aureus* 35, 47, 446
 - Methotrexate, tumour resistance and novel drugs for 34
 - N-Methyl-D-aspartate (NMDA) receptors, see NMDA receptors
 - 2-Methyl-3-[2(S)-pyrrolidinylmethoxy]pyridine 247
 - Michael addition 216
 - Microbacterium*, biocatalysis 520
 - Microbial models, drug metabolism 397
 - Microcide Pharmaceuticals, Tularik screening programme 393
 - Microfluidic pumps 253, 306
 - Microplates 174–175, 253–254
 - 384 wells 40–41, 306, 385
 - assay miniaturization 503
 - biochemical assays on R2 robotic system 503
 - liquid-handling systems 395
 - 1536 wells 306, 355, 504
 - credit-card sized chips 253–254, 306
 - see also Gene chip technology
 - current and future technology 174–175
 - formats (384/864/1536 wells) 306
 - history 174
 - structure 174
 - Web sites of suppliers 174
 - Midazolam 484
 - Migraine
 - prophylaxis/treatment, serotonergic drugs 297
 - serotonin receptors 296–298
 - MiKasome, Phase I trial 452
 - Millennium Pharmaceuticals Inc, appointment 452
 - Miniaturization, high-throughput screening 306, 381, 503
 - Mitochondria
 - dysfunction in neuronal cells 226
 - Mitokor's research 211
 - Mitokor, appointment of W. Moos 211–212
 - Mitoxantrone 489
 - MK0499 519, 520
 - MK0507, biocatalysis 523–524
 - MK0571 517
 - MK0591 326, 327
 - MK383 (Tirofiban) 195, 196
 - MK966 326, 327
 - Moclobemide 482
 - Molecular cloning, phosphodiesterase 4 (PDE4) 92–93
 - Molecular complementarity analysis 134–135
 - Molecular diversity
 - combinatorial chemistry and (BR) 177–178
 - multicopy sampling 229–234
 - patents 363

- Molecular electron density 'Lego' assembler (MEDLA) 133–134
- Molecular genetic profiling* (CR) 310–311
- Molecular modelling
book review 364
software on Internet 40
- Molecular shape, fuzzy molecular electron density fragments 132–137
- Molecular similarity, electron density 134–135
- Monoclonal antibodies
 $\alpha\beta$ T-cell receptor 433
angiogenesis inhibition 60
CD4 cells 433
selectins 188
TNF- α , *see* Tumour necrosis factor- α (TNF- α)
- Moos, W., appointment to Mitokor 211–212
- Morphine, codeine conversion and racial differences in CYP2D6 456
- Mortierella alpina* 520
- MPPB (methylphenylpropyl-barbituric acid), stereoselectivity 141
- MUC2* gene 207
- Mucin
airway expression 207
secretion, inhibitors 207
- Mucosal delivery, drugs 402–404
- Mulliken's population analysis 133
- Multicopy sampling 229–234
- Multidrug resistance (MDR) 510
- Multiple sclerosis, neurotransmitter-based drug 450
- Muscarinic analgesics 247–248
- Muscarinic M_1 antagonist 341–350
in CNS 344
compounds in development 343
in digestive tract 343
imaging agents 348–349
memory impairment 345
modeling 349
nonselective 344
in respiratory tract 343
structure–activity relationships 345–348
- Muscarinic M_3 antagonist 343
- Muscarinic receptors 342
in CNS 344–345
in digestive tract 342–343
in respiratory tract 343–344
subtypes 342
- Muscle, troponin C 508
- Muscle cell, membrane, digitalis effect 111
- Mutations, genome scanning for 310–311
- Mycotoxins 520
- Myoglobin, multicopy sampling 229
- N**
- Na⁺/K⁺-ATPase 111
digitalis receptor 111, 112
isoforms 112
inotropy/toxicity-linked 113–114
ouabain-like inhibitor 393
- Nafadotride 337
- Nanolitre dispensing 396
- Nano-ultra fluorescence-based technology 159
- Naproxen 481, 513–514
biocatalysis and (S)-isomer 514
- Naratriptan 298
- NASA, microplates collaboration 175
- Natural products 505
biodiversity and supply 258
chirality 139
combinatorial biosynthesis 505–506
combinatorial technology with 258–259
cytotoxic 79
hybrid 506
isolation/generation 256–257
molecular pharmacognosy 243–246
new antibiotics 257–258
new antifungal agents 258
new drugs from 257–258, 353, 555
new technologies/approaches 256–259
non-catechol-containing, HIV integrase inhibition 495
sample profiling 257
- Natural Products Drug Discovery: new technologies to increase speed and efficiency* (CR) 256–259
- Nausea, phosphodiesterase 4 (PDE4) inhibitors inducing 99
- Nelfinavir 261
clinical results 269–270
discovery/design 268
- NemaPharm 399
- Nematodes 399–400
model organism 399
screening assays 399–400
- Neovascularization 50–51
see also Angiogenesis
- Netropsin 490
- Neuraxis, joint venture between Medeval and Cerebrus 28
- Neurex Corporation, Phase III trial for calcium channel blocker 121
- Neuroactive compounds, from Hawaiian plants 177
- Neurodegenerative diseases 36
free radicals role 225
mechanisms of neuronal cell death 219–228
- Neurofuzzy systems 43, 45
- Neurokinin, NK₁ receptor antagonist 162, 501
- Neuromedin B (NMB) 80
- nonpeptide antagonists 80
- Neuronal cell injury/death 219–228
blockade 222–226
intracellular targets 224–226
necrosis 219
- Neuropeptide, patenting 25–28
- Neuropeptide Y 19, 504
patenting 25–28
receptors as drug target 504
receptor types 19–20
Y₁ receptor 19
Y₁ receptor antagonists 19–24
applications/functions 23–24
high potency 22–23
PYX-1 and PYX-2 20
rational design 21–22
Y₅-like receptors in epilepsy 504
- Neuroprotective agents 219–228
- Neurotoxic amino acid, new 353
- Neurotrophic factors 226
- Neutrophil elastase, inhibitors 162
- Neutrophils, activation and chloride ion efflux during 38
- New Chemical Entities (NCEs) 1
numbers 73
- New Combinatorial Chemistry* (CR) 214–217
- New Drug Application (NDA) 1
- NeXstar Pharmaceuticals, MiKasome Phase I trial 452
- NF- κ B 331
activation 331
inhibition 434
nuclear translocation 125
- NGD94-1 362, 363
- Nicardipine 517
- Nicotinic acetylcholine receptor ligand 247
- NIDDM, *see* Non-insulin-dependent diabetes mellitus (NIDDM)
- Nifedipine 517
stereoselectivity 144
- Ninhydrin-based assays 103
- Nitrendipine 517
stereoselectivity 144
- Nitric oxide
blockade in neuroprotection 225
control of release 3
inhibition of endothelin-1 formation 85
medical applications 3
- Nitric oxide synthase, inhibitors 225, 429
- Nitrogen mustard prodrugs 302
- NK₁ antagonists 162, 501
- NMDA receptors 222
antagonists 220, 222–223
subunits 222

- NO, *see* Nitric oxide
Nocardia salmonicolor 520
 Nonapeptide, cyclic 391
 Non-insulin-dependent diabetes mellitus (NIDDM)
 animal models 129
 complications 129
 α -glucosidase inhibitors 248
 new drugs and approaches 128–129
 Nonpeptide ligand 165
 see also Peptidomimetic drugs
Non-Insulin Dependent Diabetes: Advances in Understanding & New Therapeutic Targets (CR) 128–129
 Non-racemic mixtures, of enantiomers 127
 Non-steroidal anti-inflammatory drugs
 in arthritis 427
 biocatalysis 513–514
 improved drugs 428–429
 5'-Noraristeromycin 236
 Nortopsentin D, cytotoxic analogue 206
 'Not invented here' syndrome 312
 Novartis, information technology in R&D strategy 167
 NPS Pharmaceuticals 359–361
 NPY, *see* Neuropeptide Y
 Nuclear magnetic resonance (NMR)
 gel-phase 469–470
 high-resolution techniques 468–478
 high-throughput 474–477
 magic-angle spinning (MAS) 104–105, 470–474
 solid-phase reaction analysis 103–106
 solution-phase 474–477
 Nuclear receptors, modulators 331
 Nuclear translocation, NF- κ B 125
 Nucleoside, L-enantiomer 237
 Nucleoside analogues, antiviral activity 235–242
 Nucleotides, as HIV integrase inhibitors 488–489
- O**
 Obesity
 animal models 129
 β_3 -agonists 363
 new drug targets 164
 prevention by neuropeptide Y₁ receptor antagonists 24
 TNF- α role 128
 Obviousness, Biogen v. Medeva patent dispute 118–119
 Octanol 481
 Oestrogen receptors, selective modulators 351
 Oligofingerprinting 319, 321
 Oligonucleotides
 angiogenesis inhibitors 61
 arrays 321
- Olomoucine 208
 Omeprazole 343, 482
 One bead-one compound (OBOC) libraries, anticancer agents 124
 OPC14117 226
 Opioid agonists, kappa, lipophilic 248
 Oral bioavailability
 cyclic HIV protease inhibitors 14–16
 peptides 148–151
 Oral delivery, drugs 402–404
Oral & Mucosal Delivery Systems for Macromolecules (CR) 402–404
 Orbofiban 195
 Orchid Computers 253, 306
 Orevactaene 555
 Orphan genes 510
 Osteoarthritis, drug advances 428–435
 Osteopontin 198
 Osteoporosis, $\alpha_v\beta_3$ integrin antagonists 197
 Osteoprotegerin 510
 Ouabain-like inhibitor of Na⁺/K⁺-ATPase 393
 Outsourced programmes 29–33
 Outsourcing
 combinatorial chemistry companies 307–308
 in pharmaceutical industry (BR) 178
 2-Oxaisocephems 162
 Oxazolidinones 48
 Oxford Diversity 214, 307
 Oxford Molecular Group plc 170
- P**
 p21 proteins 123
 p38 MAP kinase 431
 p53 tumor suppressor, drug target 164
 P170 glycoprotein 142
 Paclitaxel 87
 see also Taxol
 'Pair system' for post-doctoral research 3
 Pancreatic polypeptide, potency 21
 Pancreatic proteases 150–151
 Parkinson's disease 36
 dopamine therapy 333
 free radicals role 225
 Mitokor's research collaboration 211
 muscarinic antagonists 341
 muscarinic receptors 344
 SIB1508Y Phase I trial 498
 Particle size distribution, late-stage candidates 424
 Partition coefficients 417
 as function of pH 421
 Partnerships
 monitoring performance and quality 29–33
 small companies 202–203
 Patenting, neuropeptide 25–28
 Patents 117
- Biogen v. Medeva case 117–121
 combinatorial technology 37
 molecular diversity 363
 obviousness 118–119
 reforms and implications (BR) 130
 sufficiency/insufficiency 119–120
 Pattern recognition techniques 45
 PD069185 (endothelin-1 receptor antagonist) 86
 PD98059 327
 PD134308 288, 289
 PD136450 288
 PD150714 348
 PD153035 327, 330
 PD156707 (endothelin-1 receptor antagonist) 86
 PD160170 23
 PECAM-1 198
 Penicillin acylase 529
 Penicillins
 biocatalysis 527–528
 solid-phase synthesis 556–557
 Pentagastrin 283
 Pentamidine 490
 Pentoxifylline 278, 430
 clinical studies 278–279
 Peptic ulcers
 CCK₈/gastric receptor antagonists 283–293
 muscarinic M₁ antagonist treatment 343
 Peptidases, brush-border 151
 Peptide(s)
 cell-permeable import, target validation 124
 HIV integrase inhibitors 496–497
 as 'magic bullets' 124–125
 oral bioavailability 148–151
 oral and mucosal delivery 402
 receptors, new ligands 38
 Peptide analogues 165
 see also Peptidomimetic drugs
 Peptide isosteres, cyclization 12
 Peptidomimetics 152, 254–256
 bioavailability 166
 combinatorial chemistry and 255–256
 cyclic templates 255
 definition 165
 design 165–167
 HIV integrase inhibitors 496–497
 interleukin-1 β -converting enzyme (ICE) inhibitors 391
 marketing 255
 scaffolds in rational design 166
 stability and selectivity 165–166
 thrombin inhibitor 445

- Peptidomimetics and Small Molecule Design* (CR) 254–256
- Peripheral vascular diseases, serotonergic drugs 297, 299
- Peroxidase 521
- Peroxisome proliferator-activated receptor α (PPAR α) 82, 331
- thiazolidinediones as ligands 128
- PGL microparticles, vaccine delivery 403
- pH
- partition coefficients 421
 - solubility 422
- Pharmaceutical companies
- adaptation by integration 205
 - creativity 550, 552
 - culture clashes 550
 - data management 552–553
 - decision making 552–553
 - drug discovery acceleration 547–553
 - environment for accelerated drug discovery 550, 551, 552
 - external pressures on R&D 547
 - information sources for tracking competitors 179–186
 - innovation stimulation 551, 552
 - large
 - collaboration over combinatorial biosynthesis 506
 - licensing deals 312
 - R&D 201–202
 - R&D, *see* R&D
 - sales and R&D expenditure matching 365–372
 - small
 - consortia 203
 - partnerships 202–203
 - top selling drugs and companies 121
 - win–win licensing deals 312
- Pharmaceutical industry
- consolidation 547–548
 - drug discovery alliances 29–33
 - implications of patent reform (BR) 130
 - information technology in R&D strategy 167–168
 - innovation deficit 74
 - outsourcing (BR) 178
 - R&D spending 77
 - strategic choices 72–78
- Pharmacodynamics
- antiviral nucleosides 240–241
 - stereoselectivity of drugs 142–143
- Pharmacoeconomics 438–440
- constraints in pharmaceutical companies 365–372
- Pharmacognosy 243–246
- model 244
 - molecular 243–246
 - research 243, 245–246
- Pharmacokinetics
- antiviral nucleosides 240–241
 - in elderly 66
 - enantiospecificity 141
- Pharmacopeia, collaboration
- agreement with Zeneca 130
- Pharmacophores
- 3D QSAR 462
 - mapping 44
- Pharmaprojects* 180, 181–182
- Phenacetin 480
- Phenanthroline 396
- Phenylaminopyrimidines 162
- Phenylhydroxybenzazepines 335–336
- Phenytoin 481
- Philinopsis speciosa*, kulolide from 79
- Phorbol 362
- mimetics 362
- Phosphatidic acid, inhibitors 61
- Phosphodiesterase(s) 89
- gene families 90
 - inhibitors 330–331, 430
 - TNF- α inhibition 278–279
- Phosphodiesterase 4 (PDE4) 89–90, 330
- cloning and expression 91–93
- Phosphodiesterase 4 (PDE4) inhibitors 89–101, 278, 279, 302, 331
- adverse effects 99–100
 - heterocyclic fused pyridazinones 351–352
 - interactions (Sc/Sr) 93–94
 - novel 302
 - recombinant, purification 93
 - structures 91
 - therapeutic effects 96–99
- Phospholipase A₂ inhibitors 328
- Phosphorylation, antiviral nucleosides 240, 242
- Phosphotyrosines, receptor-specific 51
- Photodynamic therapy, anticancer 449
- Physical chemical characteristics of drugs 415–426
- characterization studies 415–416
 - late-stage candidates 423–425
 - preclinical/clinical candidates 418–423
 - screening 416–418
- Phytera Inc., acquisition 175
- Picenadol, stereoselectivity 141
- Piclamilast (RP73401) 91
- Piezoelectric technology 396
- Pipenzepine, analogues 349
- Pipetting, automated devices 395
- Pipenzepine 342, 343
- Pivaloyloxybenzene derivatives 162
- Plants
- molecular pharmacognosy 243–246
 - source of novel drugs 177
 - tissue screening using sensor system 177
- Plasmodium falciparum*
- apicidin activity against histone deacetylase 82
 - novel drugs against 34
- Platelet, activation, drug target 396
- Platelet $\alpha_{IIb}\beta_3$ (GPIIb-IIIa) receptor
- antagonists 37, 195–196, 446–447
 - cyclic peptides 196
 - library 207–208
 - orally active 196
 - thromboembolism diagnosis 196
- Platelet-derived growth factor (PDGF) receptor 53, 57–58
- Platelet factor 4, angiogenic inhibitor 60
- Platelet fibrinogen receptor (GPIIb/IIIa), *see* Platelet $\alpha_{IIb}\beta_3$ (GPIIb-IIIa) receptor
- antagonists
- Plates, *see* Microplates
- PLG microparticles, as vaccine adjuvants 404
- Pneumocandin B₀ 258
- Polyanions, angiogenesis inhibitors 60
- Polycations, angiogenesis inhibitors 60
- Polyene antibiotics 35
- Poly-isoxazolines 217
- Polyketides 258–259
- novel 505–506
 - synthesis 258–259, 521–522
- Polymerase chain reaction, genetic profiling 310
- Polymers
- combinatorial 394
 - nitric oxide 3
- Polymorphism
- drug candidates 419–420
 - late-stage candidates 424
- Polymorphonuclear cells
- transendothelial migration 198
 - see also* Neutrophils
- Polypeptides, angiogenesis inhibitors 60
- Pompe's disease, α -glucosidase gene therapy 5
- Portal hypertension, serotonergic drugs 298, 298–299
- Post-doctoral system, unique 'pair system' for research 3
- Potassium channel
- ATP-sensitive openers 249, 303
 - calcium-activated 161, 391
- Potassium channel blockers 520

calcium-activated channels 161
 human T cell Kv1.3 352–353
 Preclinical compounds, reasons for rejection 397
 Pre-eclampsia, serotonergic drugs 297, 299
 Premature ageing syndromes 68
 Prescreening tests, digitalis derivatives 114
 Primaquine 489
 Principal components analysis 45
 'Privileged structure' libraries 214–215, 307–308
 Procainamide 486
 Prochiral intermediates 516–518
 Prodrugs 152
 bioreversible cyclization 153–154
 concept 152
 intestinal absorption of peptides 148–155
 nitrogen mustard 302
 Progeroid syndromes 68
 Proglumide 284, 285
 Programmed cell death, *see* Apoptosis
 Proguanil 482
 Project acceleration 1
 Project management 436–444
 see also Drug development
 Promethazine 544
 Propranolol 480
 stereoselectivity 141
 2-Propyl-4-pentenoic acid, stereoselectivity 141
 Prostaglandin, biosynthetic pathway 326
 Proteases
 in design of peptidomimetic drugs 166
 inhibitors, HIV, *see* HIV
 protease inhibitors
 thrombin receptors activated 305
 Protein kinase
 inhibitors 281–282
 p38, drugs binding 35
 Protein phosphatase inhibitors, library 208–209
 Protein–protein interactions 254
 Protein tyrosine kinases, *see* Tyrosine kinases
 P-selectin 188
 Pseudoephedrine, biocatalysis 526–527
Pseudomonas fluorescens, lipase-catalyzed reactions 514–516, 517
 Pulmonary cell, allergen-induced influx 98
 Pulmonary hypertension, serotonergic drugs 297, 298–299
 Pumps, microfluidic 253, 306
 Purine synthesis, combinatorial chemistry 208

Pyranoxanthrones 301
 Pyrazolidinones, CCK₂/gastrin receptor antagonists 289
 Pyrazolodiazepinone 447
 Pyridazinones, heterocyclic fused 351–352
 Pyridone-based peptidomimetic, interleukin-1 β -converting enzyme (ICE) inhibitors 391
 Pyrrolyl-quinoxalinediones 122
 PYX-1 and PYX-2 20

Q

QSAR 133, 457–467
 applications and problems 538–546
 contributions to drug design 545–546
 3D 457–467
 applications and problems 538–546
 contributions to drug design 545–546
 structure generation 461–462
 theory 461–462
 models, validation 545
 nonlinear relationships 460–461
 predictions and training sets 545
 theory 458
 Quality, drug discovery alliances 29–33
 Quantitative similarity–activity relationships (QSiAR) 465–466
 Quantitative structure–activity relationships, *see* QSAR
 Quercetagenin 490
 Quiescence 68
 Quinazolinones 291
 Quinpirole 336
 Quintiles, expansion and acquisition 45
 Quinuclidine squalene synthase, inhibitors 249
 Quinuclidinyl esters 348

R

R&D
 alternative to classical structure 204
 architecture 200–205
 box-girder architecture 203–204
 buttressing in large companies 201–202
 company productivity 73–74
 drug development interface, management 436–444
 expenditure and sales expectations matching 365–372
 information sources for tracking competitors 179–186
 pressures on pharmaceutical companies 547

productivity of pharmaceutical companies 73–74
 spending in pharmaceutical industry 77
 strategy, IT in pharmaceutical industry 167–168
 strategy (BR) 313
 vertical integration 200–201
R&D Focus 180, 182
R&D Insight 180, 182–183
 Racemates, enantiomers versus 127, 139
 Racemic mixtures 127
 nucleosides 237
 Racemic switches 127
 Raclopride 337
 Raloxifene 351
 RAPIDD, research aid for data retrieval 44
 Ras farnesyl protein transferase inhibitors 123
 Ras proteins 123
 p21, inhibition of membrane association 499
 Rational drug design
 combinatorial chemistry and 81
 neuropeptide Y₁ receptor antagonists 21–22
 peptidomimetic drugs 166
 see also Drug design
 Reactive oxygen species (ROS) 225, 226
 Receptors
 3D QSARs 540
 neuropeptide Y 19–20, 504
 signal transduction (BR) 454
 stereoselective 139
 water-soluble synthetic 447
 see also specific receptors
 Receptor tyrosine kinases (RTKs)
 in angiogenesis 52–58
 families 55
 inhibition, therapeutic strategies 58–59
 role in angiogenesis 58
 target for angiogenesis inhibition 50–63
 types 53–58
 Records, microplate results 175
 5 α -Reductase
 inhibitors 500
 isoenzymes 500
 Regulatory issue, chirality in drugs 145–146
 Remote sensing technologies 381
 REM resin 216
 Renin inhibitors 83, 263
 future prospects 83
 Reporter gene transcription, fluorescence resonance energy transfer 158
 Research alliances, monitoring performance and quality 29–33
 Research centres 76
 Resins
 colorimetric assays in solid-phase synthesis 103

- polystyrene, for solid-phase organic synthesis 454
- Respiratory tract, M₁ receptors 343–344
- Retinal disease, ischemia, anti-angiogenic drugs in 61
- Retinal neovascularization, potential inhibitors 61
- Retinal photoreceptor cells, c-fos-mediated apoptosis 305
- Retinitis pigmentosa, c-fos-mediated apoptosis of retinal cells 305
- Retinoic acid receptors (RARs) antagonists 501–502
RAR-specific synthetic retinoids 498
- RGD mimetics, antithrombotic 34
- Rheumatoid arthritis
angiogenesis inhibitors application 61
drug advances 427–435
immunosuppressive/immunomodulatory approaches 432–434
- Rhinovirus, inhibitors 124
- Ribavirin, biocatalysis 527
- Ribophostin 214
- Ribose, in D-myo-inositol-(1,4,5)-trisphosphate analogue 214
- Ribozymes, targeting vascular endothelial growth factor (VEGF) receptors 61
- Risk management strategy 442–443
- Risperazine 343
- Ritonavir 83, 255, 261
clinical results 268–269
discovery/design 264–265
pharmacokinetics 15
as substrate and inhibitor of CYP2D6 483
- Rizatriptan 297, 298
- Ro201724 [phosphodiesterase 4 (PDE4) inhibitor] 91
- Ro319790 432
- Ro323555 328, 432
- Ro449883 ($\alpha_{11b}\beta_3$ receptor antagonist) 195
- Ro452081 (TNF- α antagonist) 276, 429
- Ro468443 (endothelin-1 receptor antagonist) 86
- Ro483657 ($\alpha_{11b}\beta_3$ receptor antagonist) 195
- Robotics
high-throughput screening 209, 251, 379, 385
liquid-handling for automated combinatorial synthesis 41
R2 system, 384-well biochemical assays 503
sample processors 395
- Robots, large-scale thermocycling 322
- Robustaflavone 555
- Roche Laboratories, FDA approval for FEMSTAT 130
- Rolipram 89, 91, 95, 278, 430
- Root-mean-square deviation (RMSD) 231
- Rosmarinic acid 491
- RP59500 (Synercid®) 47, 48
- RP69758 289
- RP72540 289
- RP73870 289
- RS25344 [phosphodiesterase 4 (PDE4) inhibitor] 91
- RU64004 47, 48
- RU66647 47, 48
- 'Rule of 75' 362
- Rumor Mill, Web site 2
- S**
- Sales, forecasts and R&D expenditure 365–370
- Salmonella*-HIV vaccine 404
- Sample profiling, natural products 257
- Sampling
conformational 230
locally enhanced (LES) 229
multicopy 229–234
- Saponin, uterine contraction stimulation 353
- Saquinavir 83, 261, 263–264
clinical results 268
discovery/design 263–264
pharmacokinetics 15
- SB203580 327, 331, 430
- SB207499 [phosphodiesterase 4 (PDE4) inhibitor] 91
- SB208651 ($\alpha_{11b}\beta_3$ receptor antagonist) 195
- SB209670 (endothelin-1 receptor antagonist) 86
- Scaffold
glutamine piperazinyl 255–256
rational design of peptidomimetic drugs 166
xanthines as 354
- Scavenger molecules, CATNAPs as 36
- SCH39166 336
- SCH56592, synthesis 522
- Schizophrenia, dopamine D₄ receptor antagonists 362
- Scientific writing (BR) 5
- Scintillation proximity assay (SPA) 373, 374
- Scopolamine 342, 345
- Scotia Pharmaceuticals, lipid-based therapeutics 449–450
- SCOUT-Scan method 475
- Screening
false positives 382–384
infrastructure for 42
plant tissues using sensor system 177
primary 374
rapid drug discovery and 357–358
- programme management 42
- time-resolved fluorometry 373–381
see also High-throughput screening
- Selectin–integrin models 197
- Selectins 188–189
antibodies and antagonists 188–189
inhibitors 189
- Selective oestrogen receptor modulators (SERMs) 351
- Selenon itrates 217
- Self-organizing maps 45
- Senescent cells 66
ageing bodies relationship 67–68
cultures 64–71
gene expression changes 69–70
indicators/assays 68
pharmaceutical potential 70
phenotype 68–70
size/surface changes 69
- Sepbox 257
- Serine/threonine protein phosphatase inhibitors 208–209
- Serotonin receptors, *see* 5-Hydroxytryptamine (5-HT) receptors
- Service companies, in combinatorial chemistry 307–308
- Sialic acid, binding site mapping on influenza coat protein 231
- SIB1508Y, Phase I trial 498
- SIBIA Neurosciences Inc., SIB1508Y Phase I trial 498
- Signaling
 β_3 integrins 125
ceramide-mediated 558
cytokine, inhibition 430–431
regulation by integrins 189–190
- Signal transduction
book review 454
manic depression 214
neuronal cells 227
receptor tyrosine kinases (RTKs) role 51–52, 55
- Single-bead encoded libraries 215–216
- Sitosterol, biotransformation 529–530
- SKF38393 335–336
- SLT Fluostar fluorimeter 385–390
- SLT Spectra Image colorimeter 385–390
- Small molecules
angiogenesis inhibitors 60–61
design 254–256
fuzzy molecular electron density fragments 132–137

- narrow drug discovery approach 449
 new drugs in arthritis 428
 nonpeptide, imitating proteins 254
 SmithKline Beecham, BioIndustry Association Patron 4
 SmithKline Beecham Biologicals, Phase III trial for vaccine against Lyme disease 130
 Snake venom metalloprotease (SVMP) 353
 SNXIII (calcium channel blocker) 224
 Phase III trial 121
 Society for Biomolecular Screening 361
 Software, molecular modelling, on Internet 40
 Solid-phase chemistry
 colorimetric assays 103
 FTIR monitoring 37, 106–107
 library generation 102–189
 mass spectrometric analysis 107–108
 NMR spectroscopy 103–106
 reactions and new developments 217
 small-scale cleavage and analysis 102–103
 Solid-phase organic synthesis
 analytical techniques 102–189
 macroporous polystyrene resin for 454
 see also Solid-phase chemistry
 Solid-phase synthesis
 benzodiazepinediones 304
 high-resolution NMR 468–478
 lavendustin A 208
 new strategies 214
 penicillins 556–557
 spiroindolines 250
 Solid-state properties, drug substances 416
 Solid-state stability 420–421
 Solid tumours, angiogenesis in 51
 Solubility
 aqueous 418
 as function of pH 422
 in solvents 423
 Soluble adhesion molecules 198–199
 Solution, stability 425
 Solution-phase synthesis
 2-aminothiazoles 216
 benzoxazepinones 215
 Solution properties, drug substances 416
 Solvents, in high-resolution NMR 472, 475
 SpaceCrunch 169
 Sparfloxacin 47, 48
 Spatially arrayed mixture technology (SpAM) 305
 Spectroscopic characterization, drug substances 415–416
 Spectroscopy, NMR, *see* Nuclear magnetic resonance (NMR)
 Sphingomyelinase 70, 558
 Spiders, venom from 359–361
 Spiperone 337
 Spiroglumide 284, 285
 derivatives 285–286
 Spiroindane secretagogues 302
 Spiroindolines, solid-phase synthesis 250
 Spirotramine 346
 Sporandol 392
 Squalene synthase, inhibitors 249
 Squalene synthetase, inhibitors 80
 SR120107A (Sanofi) 23
 SR120819A (Sanofi) 23
 Stability 418
 metabolic, evaluation methods 402
 solid-state 420–421
 solution 423, 425
Staphylococcus aureus, methicillin-resistant 35, 47, 446
Staphylococcus epidermidis, antibiotic resistance 47
 Stavudine 236
 Stereochemistry 127
 fostricin (C1920) 248
 Stereogenic centres, nucleosides 237–238
 Stereoselectivity
 antiviral nucleosides 236–238
 drug action 138–147
 drug actions, at ion channels 142–145
 specific drugs 140, 141
 see also Enantiomers
 Steroids, biotransformation 529–530
 Stictic acid 495
 Strategic alliances 550
Streptococcus pneumoniae, antibiotic resistance 47
 Streptogramins, combinations under development 48
Streptomyces lividans 259
 Stromelysin 432
 nonpeptide inhibitors 447–448
 novel inhibitors 81
 Structure–activity relationships 236–238
 in molecular pharmacognosy 244–245
 muscarinic M₁ antagonists 345–348
 nonlinear 460–461
 quantitative, *see* QSAR
 Structure–reactivity relationships (SRR) 384
 Structure–structure relationship, molecular pharmacognosy 244–245
 Strychnocarpine 245
 SU4984 355
 SU5402 355
 Subtilisin 518
 Sulfonamides 496
 Sulfones 496
 Sulfonic acids 496
 Sulfonilamides 496
 Sulfoquinovosyl diacylglycerol (SQDG) 245
 Sulphaphenazole 481
 Sulphobetaines 80
 4-Sulphonamidoaniline tertiary carbinols 303
 Sumatriptan 296–298
 SUNBOR (Suntory Institute for Bio-organic Research) 3
 SuperGen, collaborative agreement 450
 Suramine 496
 Surface area, late-stage candidates 424
 Sympathetic nervous system, digitalis effect 111
 Systemic lupus erythematosus (SLE), inhibitors 163
T
 Tacrine 480
 TAK029 ($\alpha_{11b}\beta_3$ receptor antagonist) 195
 TAK044, endothelin-1 (ET-1) receptor antagonist 87
 TAK603 434
 Target product profile (TPP) 436–438
 barriers to drugs 439
 Target validation 124
 Taxoids
 second generation 161
 3'-trifluoromethyl 161
 Taxol
 alternatives, development 87–88
 biocatalysis 514–515, 525
 electron density images 136
 Taxotere 87
 Tazarotene 498
 T-cell receptor
 $\alpha\beta$, antibodies 433
 peptides, as vaccines in arthritis 433
 T cells
 function, inhibition 433
 potassium channel Kv1.3, blockers 352–353
 subset ablation 433
 Tecogalan (DS4152) 60
 Teflon grafts, effects of nitric oxide polymers 3
 Telenzepine 342
 Tenidap 428, 429
 Terfenadine 483, 484
 Terphenyls 122
 Tetracyclines, modified 47
 Δ^1 -Tetrahydrocannabinol 481
 Tetrahydropyranyl (THP), purine synthesis 208
 Tetrahydropyrimidinones 11, 12
 Thalidomide 61, 430

- absorption and solubility 277–278
 - analogues 278, 430
 - biological effects 140
 - side effects 140, 277
 - therapeutic uses 277
 - TNF- α synthesis inhibition 276–278, 430
 - Theophylline 91, 278
 - Therapeutic index
 - digitalis 110–111
 - enantiomers 127
 - Thermoanaerobium brokii* 520
 - Thermolysin, inhibitors 543
 - Thiazolidinediones 128
 - Thiolactone 214
 - Thiophene-2-alkylsulphonamides, 5-lipoxygenase inhibitors 352
 - Thiorphan 543
 - Thrombin
 - inhibitors 249, 445
 - collaboration agreement 311
 - peptidomimetic 445
 - lipophilic binding pocket 249
 - receptor 305
 - protease-activated (PAR3) 305
 - Thromboembolism, diagnosis, integrin $\alpha_{IIb}\beta_3$ antagonists 196
 - Thrombospondins 198
 - Tie-1 receptor kinases 56
 - Tie-2 receptor kinases 53, 55, 56
 - Tight junctions 149
 - Time-resolved fluorometry 373–381
 - automation 378–381
 - fluorescence quenching 378
 - free format assay 380
 - heterogeneous assays 376–377
 - high-throughput screening 156–157, 380–381
 - homogeneous assays 157, 377–378
 - lanthanide chelates and labels 376
 - principles/basics 375–376
 - Tirilazad 225
 - Tirofiban 195, 196
 - TNP351 34
 - Tocainide 486
 - Tolbutamide 481
 - Topoisomerase inhibitors 489
 - Toxins, investigation at SUNBOR 3
 - Toxoplasma*, apicidin activity against histone deacetylase 82
 - TRAIL 448
 - Transcellular pathway 149
 - Transcription, changes in senescent cells 70
 - Transcription factor
 - peroxisome proliferator-activated receptor α (PPAR α) 82
 - see also NF- κ B
 - Transferrin receptor, downregulation in senescent cells 70
 - Transforming growth factor- β 1 (TGF- β 1), neuroprotection 225
 - Transgenic models 510
 - Transporters, 3D QSARs 540
 - Transport process, across intestinal mucosa 149–151
 - Trials, see Clinical trials
 - Trichosporon capitatum*, biocatalysis 520
 - 3'-Trifluoromethyl taxoids 161
 - Trihexyphenidyl 344, 345
 - analogues 347
 - Tripeptides, number from standard amino acids 40
 - Trophix Pharmaceuticals, glycine re-uptake inhibitors 303
 - Troponin C
 - cardiac muscle 508
 - skeletal muscle 508
 - Trovafloxacin 47, 48
 - Trusopt, glaucoma treatment 523
 - Tularik screening programme 393
 - Tumour
 - angiogenic and anti-angiogenic factors 53
 - anti-angiogenic strategies/agents 58–59, 60–61
 - methotrexate-resistant 34
 - regression, $\alpha_v\beta_3$ integrin antagonists 196
 - solid, angiogenesis in 51
 - see also Cancer
 - Tumour necrosis factor (TNF)
 - apoptosis pathway 448
 - death receptor-4 (DR4) 448
 - inhibitors 35
 - neutrophil activation and chloride ion efflux 38
 - soluble receptors as TNF- α antagonists 276
 - Tumour necrosis factor- α (TNF- α)
 - 273
 - antibodies 275–276, 429
 - cA2 275–276, 429
 - CDP571 276, 429
 - MAK 195F 276
 - functions 273
 - overproduction 274–275
 - role in insulin resistance 128
 - synthesis 273–274, 329
 - Tumour necrosis factor- α (TNF- α) inhibitors
 - adenosine agonists 280–281
 - antibodies, see Tumour necrosis factor- α (TNF- α)
 - matrix metalloproteinase inhibitors 279–280, 431, 432
 - phosphodiesterase inhibitors 278–279, 302, 430
 - protein kinase inhibitors 281–282
 - thalidomide and analogues 276–278, 430
 - therapeutic potential 273–282
 - TNF (soluble) receptors 276
 - Tumour necrosis factor convertase 329, 431
 - Tumour suppressor genes, p53, as drug target 164
 - Tyrophostin AG126 207
 - Tyrosine kinases
 - 1ABL, electron density images 137
 - ATP binding site, blockers 355
 - domain in receptor tyrosine kinases (RTKs) 51
 - drugs targeting 355
 - inhibitors 330
 - as HIV integrase inhibitors 491
 - see also Receptor tyrosine kinases (RTKs)
 - Tyrphostins 281–282, 491, 492
- U**
- U96988, pharmacokinetics 16
 - U100592 47, 48
 - U100766 47, 48
 - U103017, pharmacokinetics 16
 - Ubiquitin-specific protease, HSV1 expression 250
 - UCL1530, selective SK $_Ca$ blocker 161
 - Ultra-high-throughput screening
 - Bristol-Myers Squibb agreement 49
 - EVOTEC BioSystems 209
 - Ureas
 - cyclic, see Cyclic ureas
 - heterocyclic 123
 - library, rhinovirus inhibitors 124
 - trisubstituted as ACAT inhibitors 352
 - Ureidoacetamides 289–290
 - Ureidobenzazepines 290–291
 - Ureidomethylcarbamoylphenylketones 555
 - Urokinase receptor antagonists 61
 - Uterine contractions, saponin stimulating 353
- V**
- Vaccaroid A 353
 - Vaccination, oral, immune response 402–403
 - Vaccines
 - bacterial vectors 404
 - DNA
 - intranasal delivery 404
 - oral delivery 404
 - Lyme disease, Phase III trial 130
 - microparticle delivery system 403
 - nasal delivery route 404
 - T-cell receptor peptides 433
 - VAGISTAT, FDA clearance for marketing 160

- 'Value demonstration' 439
- Vascular cells, α_v integrin and osteopontin interaction 198
- Vascular endothelial growth factor (VEGF) 53
- antibodies 58, 60
- antisense oligonucleotide inhibitors 61
- Vascular endothelial growth factor (VEGF) receptors 54–56
- inhibition 58
- ribozymes targeting 61
- Vascular endothelium 50
- changes in senescence 69
- Vascular grafts, nitric oxide application 3
- Vascular remodeling, $\alpha_v\beta_3$ integrin role 196
- Vascular tone, endothelin role 87
- Vasodilatation, ceramide-mediated 558
- VCAM-1 190
- Venoms, spider 359–361
- Verapamil
- cardiovascular activities 145
- racemate preparation 144
- stereoselectivity at calcium channels 142, 144–145
- Vertex Pharmaceuticals, HIV protease inhibitor Phase II study 160
- Very late antigen (VLA) 191
- Viracept 83
- pharmacokinetics 15
- Virensic acid 495
- Virtual chemistry 362
- Virtual combinatorial libraries 40, 354
- Virtual molecules 39–40
- Virtu-Well technology 306
- Vitronectin 198
- Vitronectin receptor
- antagonist, nonpeptide 501
- see also* Integrins, $\alpha_v\beta_3$
- VLA-4 191
- Vomiting, phosphodiesterase 4 (PDE4) inhibitors inducing 99–100
- VRML (virtual reality markup language) 39
- VX478
- HIV protease inhibitor 84
- pharmacokinetics 15
- W**
- Warfarin 481
- Warner-Lambert, Phase III trial for calcium channel blocker 121
- Water, structural, cyclic HIV protease inhibitor design 6–18
- WebLab Viewer 40
- Werner's syndrome 68
- 'WET' solvent-suppression, in high-resolution NMR 475
- World Wide Web, *see* Internet
- Worms, in drug discovery 399–400
- Writing, scientific (BR) 5
- WY47288 326, 327
- Wyeth-Ayerst, rights to thrombin inhibitors 311
- X**
- Xanthine oxidase 520–521
- Xanthines, as library scaffold 354
- Xenilofiban 195
- Xenobiotics 479
- Xenova Ltd, research alliances and monitoring performance 29–33
- XM311, pharmacokinetics 16
- Y**
- YM43611 337
- YMO22 287, 288
- Z**
- Zafirlukast 326, 327
- Zalcitabine 236
- ZD611 (endothelin A antagonist) 249
- (S)-Zearalenone 519, 520
- Zeneca
- collaboration agreement with Pharmacopeia 130
- information technology in R&D strategy 167–168
- new combinatorial chemistry strategies 214
- solid-phase synthesis 214–215
- Zidovudine 236
- Zif268, multicopy sampling of combinatorial libraries 232
- Zileuton 326, 327
- information in databases 183
- Zinc finger, multicopy sampling of combinatorial libraries 232
- Ziracin 257
- Zizyphosides 244
- Zolmitriptan 298
- Zonula occludens 149